GSK’s AWP Pricing Settlement Includes Expanded Training Of Sales Reps
Executive Summary
GlaxoSmithKline's $150 mil. settlement with the Department of Justice requires the company to expand its compliance training for its sales reps
You may also be interested in...
AWP Litigation Increases As Justice Dept. Sues Roxane For Price Inflation
Another lawsuit has been added to the tangle of litigation over average wholesale drug pricing
AWP Litigation Increases As Justice Dept. Sues Roxane For Price Inflation
Another lawsuit has been added to the tangle of litigation over average wholesale drug pricing
GSK AWP settlement
GlaxoSmithKline settles average wholesale price class action litigation for $70 mil., the company announces Aug. 10. Plaintiffs alleged that GSK inflated certain AWPs - primarily for antiemetics Zofran and Kytril. The settlement, which covers all claims filed in Boston federal court, resolves most of the AWP litigation pending against GSK, company says. GSK reached civil settlements with six state attorneys general as part of a September settlement with the Department of Justice over Zofran and Kytril pricing (1"The Pink Sheet" Sept. 26, 2005, p. 6). Reportedly, there are more than a dozen remaining defendants involved in the AWP litigation, including AstraZeneca and Bristol-Myers Squibb...